Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 163

1.

Abiraterone acetate for the treatment of prostate cancer.

Ryan CJ, Cheng ML.

Expert Opin Pharmacother. 2013 Jan;14(1):91-6. doi: 10.1517/14656566.2013.745852. Epub 2012 Nov 30. Review.

PMID:
23199349
2.

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, de Bono JS.

J Clin Oncol. 2008 Oct 1;26(28):4563-71. doi: 10.1200/JCO.2007.15.9749. Epub 2008 Jul 21. Erratum in: J Clin Oncol. 2012 May 20;30(15):1896.

PMID:
18645193
3.

New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.

Sharifi N.

Expert Opin Investig Drugs. 2010 Jul;19(7):837-46. doi: 10.1517/13543784.2010.494178. Review.

PMID:
20524793
4.

Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.

Rehman Y, Rosenberg JE.

Drug Des Devel Ther. 2012;6:13-8. doi: 10.2147/DDDT.S15850. Epub 2012 Jan 16. Review.

5.

Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.

Attard G, Reid AH, A'Hern R, Parker C, Oommen NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E, Olmos D, Sinha R, Lee G, Dowsett M, Kaye SB, Dearnaley D, Kheoh T, Molina A, de Bono JS.

J Clin Oncol. 2009 Aug 10;27(23):3742-8. doi: 10.1200/JCO.2008.20.0642. Epub 2009 May 26.

6.

Abiraterone acetate for castration resistant prostate cancer.

Shah S, Ryan C.

Expert Opin Investig Drugs. 2010 Apr;19(4):563-70. doi: 10.1517/13543781003639427. Review.

PMID:
20225998
7.

Targeting continued androgen receptor signaling in prostate cancer.

Massard C, Fizazi K.

Clin Cancer Res. 2011 Jun 15;17(12):3876-83. doi: 10.1158/1078-0432.CCR-10-2815. Review.

8.

Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy.

Cai C, Balk SP.

Endocr Relat Cancer. 2011 Aug 30;18(5):R175-82. doi: 10.1530/ERC-10-0339. Print 2011 Oct. Review.

9.

[Androgen-deprivation therapy in prostate cancer: clinical evidence and future perspectives].

Pinto F, Calarco A, Totaro A, Sacco E, Volpe A, Racioppi M, D'Addessi A, Bassi PF.

Urologia. 2010 Apr-May;77(2):71-83. Review. Italian.

PMID:
20890863
10.

The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer.

Courtney KD, Taplin ME.

Curr Opin Oncol. 2012 May;24(3):272-7. doi: 10.1097/CCO.0b013e328351059d. Review.

PMID:
22327837
11.

Abiraterone acetate, a novel adrenal inhibitor in metastatic castration-resistant prostate cancer.

Salem M, Garcia JA.

Curr Oncol Rep. 2011 Apr;13(2):92-6. doi: 10.1007/s11912-011-0153-4. Review.

PMID:
21243537
12.

Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer.

MacVicar GR, Hussain MH.

Curr Opin Oncol. 2013 May;25(3):252-60. doi: 10.1097/CCO.0b013e32835ff161. Review.

PMID:
23511665
13.

New therapies for castration-resistant prostate cancer: efficacy and safety.

Beltran H, Beer TM, Carducci MA, de Bono J, Gleave M, Hussain M, Kelly WK, Saad F, Sternberg C, Tagawa ST, Tannock IF.

Eur Urol. 2011 Aug;60(2):279-90. doi: 10.1016/j.eururo.2011.04.038. Epub 2011 May 4. Review.

PMID:
21592649
14.

New and emerging agents for the treatment of castration-resistant prostate cancer.

Higano CS, Crawford ED.

Urol Oncol. 2011 Nov-Dec;29(6 Suppl):S1-8. doi: 10.1016/j.urolonc.2011.08.013. Review.

PMID:
22074657
15.

Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone.

Efstathiou E, Titus M, Tsavachidou D, Tzelepi V, Wen S, Hoang A, Molina A, Chieffo N, Smith LA, Karlou M, Troncoso P, Logothetis CJ.

J Clin Oncol. 2012 Feb 20;30(6):637-43. doi: 10.1200/JCO.2010.33.7675. Epub 2011 Dec 19.

16.

Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.

Vis AN, Schröder FH.

BJU Int. 2009 Aug;104(4):438-48. doi: 10.1111/j.1464-410X.2009.08695.x. Epub 2009 Jun 24. Review.

17.

Metastatic castration resistant prostate cancer: current strategies of management in the Middle East.

Bazarbashi S, Bachour M, Bulbul M, Alotaibi M, Jaloudi M, Jaafar H, Mukherji D, Farah N, Alrubai T, Shamseddine A.

Crit Rev Oncol Hematol. 2014 Apr;90(1):36-48. doi: 10.1016/j.critrevonc.2013.11.001. Epub 2013 Nov 8. Review.

PMID:
24289901
18.

Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer.

Nakabayashi M, Werner L, Courtney KD, Buckle G, Oh WK, Bubley GJ, Hayes JH, Weckstein D, Elfiky A, Sims DM, Kantoff PW, Taplin ME.

BJU Int. 2012 Dec;110(11):1729-35. doi: 10.1111/j.1464-410X.2012.11456.x. Epub 2012 Aug 29.

19.

Abiraterone acetate: a novel drug for castration-resistant prostate carcinoma.

Nandha R.

J Postgrad Med. 2012 Jul-Sep;58(3):203-6. Review.

20.

Novel strategies in the treatment of castration-resistant prostate cancer (Review).

Marech I, Vacca A, Ranieri G, Gnoni A, Dammacco F.

Int J Oncol. 2012 May;40(5):1313-20. doi: 10.3892/ijo.2012.1364. Epub 2012 Feb 9. Review.

PMID:
22322981

Supplemental Content

Support Center